Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans

Dapagliflozin, a selective sodium–glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jin-Woo Park, Jong-Min Kim, Ji Hyeon Noh, Kyoung-Ah Kim, Hyewon Chung, EunJi Kim, Minja Kang, Ji-Young Park
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2022-03-01
Serie:	Pharmaceutics
Soggetti:	dapagliflozin linagliptin fixed-dose combination products bioequivalence
Accesso online:	https://www.mdpi.com/1999-4923/14/3/591
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!